Primary Immunodeficiency Clinical Trial
Official title:
Study of Safety and Efficacy of Mini-pool Intravenous Immunoglobulin (MP-IVIG) Prepared by Assiut University Hospital Blood Bank in Primary Immunodeficiency Patients
1. study the pharmacokinetics of mini-pooled intravenous immunoglobulin( MP-IVIG)
2. Study the safety and efficacy of a newly developed preparation of MP-IVIG in children
with primary immunodeficiency (PID) :
- Adverse reaction of MP-IVIG(anaphylaxis and haemolysis)( no or mild or moderate)
- Prevention of severe bacterial infection
- Improvement of general health(weight gain and mentality)
- Integration in to social live
3. Compare the efficacy of MP-IVIG to standard IVIG in children with primary
immunodeficiency (PID).
Primary immunodeficiency diseases (PID) are a heterogeneous group of inherited disorders of
the immune system, predisposing individuals to recurrent infections, allergy, autoimmunity,
and malignancies. Clinical descriptions have already been made for more than 200 PIDs, for
which over 150 forms of PID have been molecularly characterized .
A population prevalence of diagnosed PID in the United States at approximately 1 in 1,200
persons.
A part from local registration in some centres there is no national registry of PID in Egypt,
and hence, the prevalence of these disorders in the investigator's population is still
unknown .
An increasing number of PID are recognized, and effective treatments are possible. Early use
of prophylactic antibiotics and replacement immunoglobulin can prevent significant end organ
damage and improve long quality of life in these patients .
Immunoglobulin G (IgG) is an essential plasma derived medicine that is lacking in developing
countries .IgG shortages leave immune deficient patients without treatment, exposing them to
devastating recurrent infections from local pathogens. A simple and practical method for
producing IgG from normal plasma collected in developing countries is needed to provide
better, faster access to IgG for patients .
Magdy EL-Ekiaby, et al 2010 introduce the concept of small-scale ("minipool") plasma
processing methods implementable with minimum infrastructural requirements. They developed
viral inactivation and protein purification technologies in single-use equipment to prepare
virally safe solvent/detergent-filtered (S/D-F) plasma Producing a 90%pure immunoglobulin
fraction in disposable single-use devices for transfusion as well as minipool S/D-F
cryoprecipitate to treat bleeding disorders.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04561115 -
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency
|
Phase 3 | |
| Recruiting |
NCT06355323 -
Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France
|
N/A | |
| Completed |
NCT04566692 -
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
|
Phase 4 | |
| Completed |
NCT01465958 -
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
|
Phase 4 | |
| Completed |
NCT01581593 -
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
|
Phase 3 | |
| Completed |
NCT02881437 -
IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
|
Phase 4 | |
| Recruiting |
NCT06092528 -
Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency
|
N/A | |
| Active, not recruiting |
NCT03576742 -
Severe Immune Cytopenia Registry Www.Sic-reg.Org
|
||
| Completed |
NCT03907241 -
CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL
|
Phase 3 | |
| Not yet recruiting |
NCT04902807 -
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
|
||
| Completed |
NCT02806986 -
Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency
|
Phase 3 | |
| Completed |
NCT03339778 -
The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations
|
N/A | |
| Enrolling by invitation |
NCT00895271 -
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
|
||
| Recruiting |
NCT03206099 -
NIAID Centralized Sequencing Protocol
|
||
| Completed |
NCT02503293 -
A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
|
Phase 4 | |
| Recruiting |
NCT03610802 -
Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies
|
||
| Completed |
NCT03815357 -
What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?
|
||
| Completed |
NCT02269163 -
Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%
|
Phase 3 | |
| Terminated |
NCT03733249 -
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02123615 -
ASIS for GAMMAGARD in Primary Immunodeficiency
|
Phase 1/Phase 2 |